Alpelisib治疗转移性乳腺癌患者的肿瘤溶解综合征。

IF 1.8 Q3 ONCOLOGY Breast Cancer : Basic and Clinical Research Pub Date : 2021-08-29 eCollection Date: 2021-01-01 DOI:10.1177/11782234211037421

Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy

{"title":"Alpelisib治疗转移性乳腺癌患者的肿瘤溶解综合征。","authors":"Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy","doi":"10.1177/11782234211037421","DOIUrl":null,"url":null,"abstract":"Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"15 ","pages":"11782234211037421"},"PeriodicalIF":1.8000,"publicationDate":"2021-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/75/10.1177_11782234211037421.PMC8408891.pdf","citationCount":"3","resultStr":"{\"title\":\"Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.\",\"authors\":\"Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy\",\"doi\":\"10.1177/11782234211037421\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.\",\"PeriodicalId\":9163,\"journal\":{\"name\":\"Breast Cancer : Basic and Clinical Research\",\"volume\":\"15 \",\"pages\":\"11782234211037421\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/75/10.1177_11782234211037421.PMC8408891.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer : Basic and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11782234211037421\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234211037421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

摘要

目的:肿瘤溶解综合征(Tumor lysis syndrome, TLS)是一种罕见但危及生命的现象，主要发生在侵袭性血液学或高化疗敏感性实体肿瘤(如高级神经内分泌癌或睾丸癌)患者中。肿瘤溶解综合征在激素受体阳性、her2阴性的乳腺癌中极为罕见。此外，alpelisib是一种新型的磷脂酰肌醇3-激酶(PI3K)抑制剂，用于治疗pik3ca突变(编码PI3K的p110α亚基的基因)，激素受体阳性的晚期乳腺癌，在非血液系统恶性肿瘤患者中从未报道过TLS。方法:在以下病例中，我们报告了一位激素受体阳性，her2阴性，pik3ca突变的转移性乳腺癌患者，在开始使用氟维司汀和阿派西布12天后发生TLS。结果:患者得到及时治疗，肾功能恢复到基线水平，无需肾替代治疗。Alpelisib以减少剂量恢复，无进一步并发症。结论:通过本病例，我们讨论了TLS的潜在并发症以及及时识别和治疗的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.

Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.

Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.

Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.

Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer : Basic and Clinical Research ONCOLOGY-

CiteScore

5.10

自引率

3.40%

发文量

审稿时长

8 weeks

期刊介绍： Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.